儿童肺炎旁积液与脓胸治疗的保守与手术方式:活体系统评价与网状Meta分析
该活体系统评价与网状Meta分析纳入11项随机对照试验共590例患儿,比较抗生素、胸管引流(联合或不联合纤溶剂)、电视辅助胸腔镜手术(VATS)和开胸剥脱术对住院时间的影响。结果显示,与单用胸管相比,胸管联合纤溶剂、开胸术和VATS均与更短住院时间相关,后三者之间无实质差异;纤溶剂相比VATS具成本优势。
要点
- 与单用胸管相比,胸管联合纤溶剂、开胸术和VATS均与更短住院时间相关。
- 胸管联合纤溶剂、开胸术和VATS三者之间住院时间无实质差异。
- 在报告医疗费用的试验中,纤溶剂相比VATS具成本优势。
核心结论
- 与单用胸管相比,其他治疗方式与更短住院时间相关。
- 纤溶剂成本较低,在住院时间和临床结局相似时值得考虑。
研究设计与样本
- 活体系统评价与网状Meta分析,检索Cochrane CENTRAL、Embase、LILACS、Ovid MEDLINE和Web of Science Core Collection。
- 纳入11项随机对照试验,共590例年龄<18岁的肺炎旁积液或脓胸患儿。
主要发现
- 与单用胸管相比,胸管联合纤溶剂、开胸术和VATS的住院时间平均差异分别为5.05天(95%CI 2.46-7.64)、6.33天(95%CI 3.17-9.50)和5.86天(95%CI 3.38-8.35)。
- 后三种干预之间住院时间无实质差异。
- 11项随机对照试验均未比较单用抗生素与其他治疗方式。
- 在报告医疗费用的试验中,纤溶剂相比VATS具成本优势。
- 无论治疗方式如何,短期和长期发病率及死亡率均非常低。
临床怎么用
- 儿童肺炎旁积液或脓胸选择治疗方式时,可考虑胸管联合纤溶剂,因其住院时间与VATS和开胸术相似且成本更低。
局限性
- 大多数试验报告了围手术期并发症和再干预需求,但描述差异显著,无法进行Meta分析。
- 无随机对照试验比较单用抗生素与其他治疗方式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The optimal treatment for community-acquired childhood pneumonia complicated by empyema remains unclear. RESEARCH QUESTION: In children with parapneumonic effusion or empyema, do hospital length of stay and other key clinical outcomes differ according to the treatment modality used? STUDY DESIGN AND METHODS: A living systematic review of randomized controlled trials (RCTs) was conducted by searching the Cochrane Central Register of Controlled Trials, Embase, Latin American and Caribbean Health Sciences Literature, Ovid MEDLINE, and Web of Science Core Collection databases. Eligible RCTs included patients aged < 18 years and compared two of the following treatment modalities: antibiotics alone, chest tube insertion with or without fibrinolytics, video-assisted thoracoscopic surgery (VATS), and decortication via thoracotomy. A network meta-analysis was performed to evaluate treatment effects on hospital length of stay (LOS), the primary outcome. RESULTS: Eleven trials including a total of 590 patients were selected for the network meta-analysis. Compared with a chest tube alone, a chest tube with fibrinolytics, thoracotomy, and VATS were all associated with shorter LOS, with a mean difference of 5.05 days (95% CI, 2.46-7.64), 6.33 days (95% CI, 3.17-9.50), and 5.86 days (95% CI, 3.38-8.35), respectively. No substantial differences in LOS were observed between the latter three interventions. None of the 11 RCTs compared antibiotics alone vs other types of treatment. Most trials reported peri-procedural complications and the need for reintervention, but the descriptions differed significantly between trials, preventing meta-analysis. In trials reporting health care-associated costs, fibrinolytics had cost advantages compared with VATS. Short- and long-term morbidity and mortality were very low, regardless of the treatment modality. INTERPRETATION: The results of this network meta-analysis showed that a chest tube alone was associated with a longer LOS compared with other treatment modalities. The lower cost associated with a chest tube plus fibrinolytics warrants consideration when choosing between treatment options, given similar LOS and clinical outcomes compared with the other modalities.
引用
- Fernandez Elviro, Longcroft-Harris, Allin, et al. Conservative and Surgical Modalities in the Management of Pediatric Parapneumonic Effusion and Empyema: A Living Systematic Review and Network Meta-Analysis. Chest. 2023. PMID: 37463660. doi:10.1016/j.chest.2023.06.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。